Syena

Syena focuses on developing T cell receptor-natural killer cell therapy (TCR-NK). The company's lead project is a potential "first-in-class" therapy targeting the NY-ESO-1 cancer antigen. The company’s products include cancer treatment technologies, enabling clinics to offer compelling new cell therapy options for patients in need.